NASDAQ:AAPG Ascentage Pharma Group International (AAPG) Stock Price, News & Analysis $20.94 +1.16 (+5.85%) Closing price 05/21/2026 03:59 PM EasternExtended Trading$20.98 +0.05 (+0.23%) As of 05/21/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Ascentage Pharma Group International Stock (NASDAQ:AAPG) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get AAPG alerts:Sign Up Key Stats Today's Range$20.10▼$20.6650-Day Range$18.56▼$27.6952-Week Range$18.56▼$48.45Volume4,829 shsAverage Volume6,274 shsMarket Capitalization$1.95 billionP/E RatioN/ADividend YieldN/APrice Target$46.67Consensus RatingBuy Company Overview Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors. Founded in 2008 by biotechnology entrepreneur Dr. Jackson Hu, Ascentage has built integrated discovery and translational research platforms based in Shanghai and Beijing. The company maintains a presence in North America with clinical and regulatory operations in the United States, and collaborates with research institutions and trial sites across Asia-Pacific, Europe and North America to advance its programs swiftly through Phase I and Phase II studies. Ascentage’s clinical development portfolio spans indications such as acute myeloid leukemia, non-Hodgkin’s lymphoma, lung cancer and colorectal cancer, with biomarker‐driven strategies to optimize patient selection and response assessment. In addition to its oncology focus, the company is exploring novel applications in viral diseases by targeting host–virus interactions through modulation of apoptotic pathways. In November 2020, Ascentage Pharma Group International completed its initial public offering on the NASDAQ Global Market under the ticker symbol “AAPG.” Led by Dr. Jackson Hu and a management team with deep expertise in oncology drug development, clinical operations and regulatory affairs, Ascentage aims to advance its pipeline toward regulatory submissions and commercialization to address significant unmet medical needs globally.AI Generated. May Contain Errors. Read More Ascentage Pharma Group International Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks82nd Percentile Overall ScoreAAPG MarketRank™: Ascentage Pharma Group International scored higher than 82% of companies evaluated by MarketBeat, and ranked 112th out of 858 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingBuy Consensus RatingAscentage Pharma Group International has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 2 strong buy ratings, 6 buy ratings, no hold ratings, and no sell ratings.Upside PotentialAscentage Pharma Group International has a consensus price target of $46.67, representing about 122.9% upside from its current price of $20.94.Amount of Analyst CoverageAscentage Pharma Group International has only been the subject of 3 research reports in the past 90 days.Read more about Ascentage Pharma Group International's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Ascentage Pharma Group International are expected to grow in the coming year, from ($1.09) to ($0.39) per share.Price to Book Value per Share RatioAscentage Pharma Group International has a P/B Ratio of 10.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.00% of the float of Ascentage Pharma Group International has been sold short.Short Interest Ratio / Days to CoverAscentage Pharma Group International has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Ascentage Pharma Group International has recently decreased by 97.77%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAscentage Pharma Group International does not currently pay a dividend.Dividend GrowthAscentage Pharma Group International does not have a long track record of dividend growth. News and Social Media2.3 / 5News Sentiment-0.35 News SentimentAscentage Pharma Group International has a news sentiment score of -0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.40 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Ascentage Pharma Group International this week, compared to 3 articles on an average week.Search Interest1 people have searched for AAPG on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Ascentage Pharma Group International to their MarketBeat watchlist in the last 30 days. Company OwnershipN/AInsider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Ascentage Pharma Group International insiders have not sold or bought any company stock.Percentage Held by InstitutionsAscentage Pharma Group International has minimal institutional ownership at this time.Read more about Ascentage Pharma Group International's insider trading history. Receive AAPG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ascentage Pharma Group International and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AAPG Stock News HeadlinesAscentage Pharma Releases Latest Clinical Data from Multiple Trials at ASCO 2026May 21 at 8:00 PM | globenewswire.comAscentage Pharma Group International (AAPG) Stock Price, Quote, News & HistoryMay 20 at 5:58 AM | benzinga.com"Computers are about to become obsolete" - George Gilder. Here’s why.George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and spotted Amazon when it was still considered a bookstore - moves followed by gains of 249,900%, 112,700%, and 216,100%. Now Gilder has identified three companies building a new chip architecture he calls the 'Trillion Dollar Triangle' - one that could make current AI data centers obsolete. One company designed it, one can build it at scale, and a third is preparing to go public. | Eagle Publishing (Ad)Ascentage Pharma Group International (NASDAQ:AAPG) Hits New 52-Week Low - What's Next?May 17, 2026 | americanbankingnews.comAscentage Pharma to Present 17 Clinical Advances at 2026 European Hematology Association CongressMay 12, 2026 | globenewswire.comAscentage Pharma to Participate in Three Upcoming Investor ConferencesMay 12, 2026 | globenewswire.comAscentage Pharma Group InternationalMay 6, 2026 | cnbc.comAscentage Pharma to Present Data from Multiple Trials, Including Three Rapid Oral Presentations, at ASCO 2026April 21, 2026 | globenewswire.comSee More Headlines AAPG Stock Analysis - Frequently Asked Questions How have AAPG shares performed this year? Ascentage Pharma Group International's stock was trading at $26.24 at the beginning of 2026. Since then, AAPG stock has decreased by 20.2% and is now trading at $20.9370. How were Ascentage Pharma Group International's earnings last quarter? Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG) released its quarterly earnings data on Wednesday, March, 25th. The company reported ($0.52) earnings per share (EPS) for the quarter. The firm earned $24.72 million during the quarter. When did Ascentage Pharma Group International IPO? Ascentage Pharma Group International (AAPG) raised $126 million in an initial public offering (IPO) on Friday, January 24th 2025. The company issued 7,325,000 shares at $17.25 per share. Who are Ascentage Pharma Group International's major shareholders? Ascentage Pharma Group International's top institutional shareholders include XY Capital Ltd (0.01%). How do I buy shares of Ascentage Pharma Group International? Shares of AAPG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings3/25/2026Today5/21/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AAPG Previous SymbolNASDAQ:AAPG CIK2023311 WebN/A Phone86 512 8555 7777FaxN/AEmployees600Year Founded2017Price Target and Rating Average Price Target for Ascentage Pharma Group International$46.67 High Price Target$51.00 Low Price Target$40.00 Potential Upside/Downside+122.9%Consensus RatingBuy Rating Score (0-4)3.25 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.57 Current Ratio1.79 Quick Ratio1.77 Sales & Book Value Annual Sales$82.10 million Price / Sales23.80 Cash FlowN/A Price / Cash FlowN/A Book Value$2.04 per share Price / Book10.26Miscellaneous Outstanding Shares93,330,000Free FloatN/AMarket Cap$1.95 billion OptionableN/A Beta0.19 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:AAPG) was last updated on 5/22/2026 by MarketBeat.com Staff. From Our PartnersSystem failure: The strongest leverage for gold…$9 trillion in U.S. debt must be refinanced in 2026 - at current rates - while the largest foreign buyers of T...Golden Portfolio | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredI had never heard of this 1888 accountAn investment account dating back to 1888 has quietly delivered average annual returns of 29% over the last 25...The Oxford Club | Sponsored"Computers are about to become obsolete" - George Gilder. Here’s why.George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...Eagle Publishing | SponsoredSpaceX controls two-thirds of all satellites - and it is about to go publicSpaceX is targeting an IPO on June 11th, with trading set to begin June 12th and the roadshow kicking off June...NXT Wave Research | SponsoredHow to Profit from Elon’s AI lab before it goes publicElon Musk's AI lab has partnered with the Department of Defense, Oracle, and Palantir - and he just filed conf...InvestorPlace | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ascentage Pharma Group International - Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Ascentage Pharma Group International With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
